ClinicalTrials.gg
CompletedNCT03093259Updated Jun 3, 2024Results posted

ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

A Phase 2 interventional study of ABX464 and Placebo oral capsule in Ulcerative Colitis, sponsored by Abivax S.A.. Completed at 19 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 221 studies in Colitis, Ulcerative with a site in Poland — 36 open to participants now, 65 under way, 31 of them phase 3. Colitis, Ulcerative · Poland.

Enrollment
198th of 215
32 · median 196
Started
2017
with 6 others
Phase 2
104 of 221
15 open now
Registered
82nd of 221
by date
Lead sponsor
7 of 221
Abivax S.A.

Among the 221 studies in Colitis, Ulcerative with a site in Poland, this one is the 198th largest by enrollment of the 215 interventional ones that give a count, is one of 7 that started in 2017, is one of 104 in phase 2, and was the 82nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

36 of the 221 studies in Colitis, Ulcerative with a site in Poland are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Colitis, Ulcerative with a site in Poland, or all of them as a file.
02

Study summary

This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month follow-up period.

Read the detailed description

This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month follow-up period.

Eligible subjects will be randomized according to a 2/1 ratio in two different groups of treatment. Randomized subjects who will receive 50 mg ABX464 orally once daily for 56 days.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • ABX464
  • Ulcerative Colitis
  • Refractory
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of moderate to severe active UC confirmed by endoscopy and histology at least 12 weeks prior to screening visit. Moderate to severe active UC defined by Mayo Clinic Score (MCS) of 6 to 12 inclusive (on a scale of 0-12). Moderate to severe active UC should be confirmed at screening visit with a centrally read MCS endoscopy score of at least 2 (on a scale of 0-3);
  • Subjects receiving oral must have been on a stable dose of prednisone or prednisone equivalent ≤20 mg/day) or on beclomethasone diproprionate (≤5mg/day) or on budesonide MMX (≤9mg/day), for ≥2 weeks before first dosing (i.e. baseline);
  • Topical corticosteroids and topical 5-aminosalicylic acid preparations must have been withdrawn ≥2 weeks before first dosing (i.e. baseline);
  • Subjects who are on oral 5-aminosalicylic acid must have been on a stable dose ≥4 weeks before first dosing (i.e. baseline);
  • Subjects who are receiving in the form of azathioprine, 6-mercaptopurine, or methotrexate needed to be on a stable dose for 4 weeks before first dosing (i.e. baseline). Subjects taking methotrexate also are advised to take folic acid 1 mg/day (or equivalent) supplementation if there is no ;
  • Subjects on probiotics (e.g., Culturelle® [Lactobacillus GG, i-Health, Inc.], Saccharomyces boulardii) must be on stable doses for 2 weeks before first dosing (i.e. baseline);
  • Subjects on antidiarrheals (e.g., loperamide, diphenoxylate with atropine) must be on stable doses for 2 weeks before first dosing (i.e. baseline);
  • Subjects who have previously received anti-tumor necrosis factor (TNF) therapy or vedolizumab must have discontinued therapy ≥8 weeks before first dosing (i.e. baseline);
  • Subjects previously treated with cyclosporine or tacrolimus must have discontinued therapy ≥4 weeks before first dosing (i.e. baseline);
  • Subjects previously treated with tube feeding, defined formula diets, or parenteral alimentation/nutrition must have discontinued treatment 3 weeks before first dosing (i.e. baseline).

Exclusion criteria

Exclusion Criteria:

  • Subject with Crohn's Disease (CD), indeterminate colitis (IC) or presence or history of fistula with CD;
  • History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma; history or is at imminent risk of colectomy;
  • History or current evidence of colonic dysplasia or adenomatous colonic polyps. Subject with severe gastrointestinal complications; e.g., short bowel syndromes, obstructing strictures, recent or planned bowel surgery, Ileostomy and/or colostomy, recent bowel perforation;
  • Subject with significant and known active infections at screening such as Infected abscess, positive for Clostridium difficile (stool antigen and toxin), CMV, TB and recent infectious hospitalization;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    ABX464 Treatment Arm

    Subjects will receive 50 mg of ABX464 orally once daily for 56 days.

    Drug: ABX464

  • Placebo comparator
    ABX464 matching placebo Treatment Arm

    Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.

    Drug: Placebo oral capsule

Interventions

  • DrugABX464

    ABX464 is a new Anti-inflammatory drug

  • DrugPlacebo oral capsule

    Placebo matching with ABX464

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment-emergent Adverse Events

    Number of treatment-emergent adverse events in the ABX464 treated subjects compared to placebo

    Time frame: Week 8

Secondary outcomes

  1. Clinical Remission

    Percentage of subjects receiving ABX464 with clinical remission according to the Total Mayo Score at Week 8 compared to placebo (primary efficacy endpoint)

    Time frame: Week 8

  2. Fecal Calprotectin

    Percentage of patients with fecal calprotectin levels \> 50µg/g at Week 8 compared to placebo

    Time frame: Week 8

  3. Total Mayo Score

    Change from baseline in Total Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 12; 12 being the worst score) - 4-component Scale: Rectal bleeding, Stool frequency, Mucosal appearance and Physician Global Assessment

    Time frame: Week 8

  4. Change in Partial Mayo Score

    Change from baseline in Partial Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 9, with 9 indicating the worst score. It is a three-component scale assessing rectal bleeding, stool frequency, and the physician's global assessment.

    Time frame: Week 8

07

Results

Posted Feb 8, 2023

Participant flow

Participant flow — Overall Study
MilestoneABX464 Treatment ArmABX464 Matching Placebo Treatment Arm
Started239
Completed219
Not completed20
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Subjects With Treatment-emergent Adverse Events

Number of treatment-emergent adverse events in the ABX464 treated subjects compared to placebo

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-emergent Adverse Events
ParticipantsABX464 Treatment ArmABX464 Matching Placebo Treatment Arm
Number of Subjects With Treatment-emergent Adverse Events185
Statistical analysis
  • ABX464 Treatment Arm vs ABX464 Matching Placebo Treatment Arm · Chi-squared · p = 0.2096
SecondaryClinical Remission

Percentage of subjects receiving ABX464 with clinical remission according to the Total Mayo Score at Week 8 compared to placebo (primary efficacy endpoint)

Time frame:
Week 8
Reported as:
Count of participants · Participants
Clinical Remission
ParticipantsABX464 Matching Placebo Treatment ArmABX464 Treatment Arm
Clinical Remission71
Statistical analysis
  • ABX464 Matching Placebo Treatment Arm vs ABX464 Treatment Arm · Chi-squared · p = 0.1588
SecondaryFecal Calprotectin

Percentage of patients with fecal calprotectin levels \> 50µg/g at Week 8 compared to placebo

Time frame:
Week 8
Reported as:
Count of participants · Participants
Fecal Calprotectin
ParticipantsABX464 Treatment ArmABX464 Matching Placebo Treatment Arm
Fecal Calprotectin158
Statistical analysis
  • ABX464 Treatment Arm vs ABX464 Matching Placebo Treatment Arm · ANCOVA · p = 0.4830
SecondaryTotal Mayo Score

Change from baseline in Total Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 12; 12 being the worst score) - 4-component Scale: Rectal bleeding, Stool frequency, Mucosal appearance and Physician Global Assessment

Time frame:
Week 8
Reported as:
Mean · score on a scale
Total Mayo Score
score on a scaleABX464 Treatment ArmABX464 Matching Placebo Treatment Arm
Total Mayo Score-4.6 ± 2.8-2.1 ± 2.5
Statistical analysis
  • ABX464 Treatment Arm vs ABX464 Matching Placebo Treatment Arm · ANCOVA · p = 0.0742
SecondaryChange in Partial Mayo Score

Change from baseline in Partial Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 9, with 9 indicating the worst score. It is a three-component scale assessing rectal bleeding, stool frequency, and the physician's global assessment.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Change in Partial Mayo Score
units on a scaleABX464 Treatment ArmABX464 Matching Placebo Treatment Arm
Change in Partial Mayo Score-3.9 ± 2.2-1.8 ± 2.0
Statistical analysis
  • ABX464 Treatment Arm vs ABX464 Matching Placebo Treatment Arm · ANCOVA · p = 0.0462

Adverse events

Collected over From baseline up to 4 weeks post last dose of study drug (up to 63 Days). Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABX4640/23 (0%)0/23 (0%)18/23 (78.3%)
Placebo0/9 (0%)1/9 (11.1%)5/9 (55.6%)
Most frequent serious events
Most frequent serious events
EventABX464Placebo
Nephrolithiasis left sideRenal and urinary disorders0/231/9
Most frequent other events
Showing 10 of 30
Most frequent other events
EventABX464Placebo
HypophosphataemiaMetabolism and nutrition disorders1/232/9
Abdominal painGastrointestinal disorders4/231/9
HeadacheNervous system disorders4/230/9
Abdominal pain upperGastrointestinal disorders3/230/9
DiarrhoeaGastrointestinal disorders0/231/9
NasopharyngitisInfections and infestations1/231/9
Iron deficiencyMetabolism and nutrition disorders1/231/9
NephrolithiasisRenal and urinary disorders0/231/9
Renal colicRenal and urinary disorders0/231/9
NauseaGastrointestinal disorders2/230/9

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of ABX464.

Age, Categorical
Age, Categorical(Participants)ABX464 Treatment ArmABX464 Matching Placebo Treatment ArmTotal
<=18 years000
Between 18 and 65 years19928
>=65 years404
Sex: Female, Male
Sex: Female, Male(Participants)ABX464 Treatment ArmABX464 Matching Placebo Treatment ArmTotal
Female11112
Male12820
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABX464 Treatment ArmABX464 Matching Placebo Treatment ArmTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White23932
More than one race000
Unknown or Not Reported000
08

Study locations

19 sites
  • Univ.-Klinik für Innere Medizin I
    Innsbruck, 6020, Austria
  • University Hospitals Leuven - campus Gasthuisberg
    Leuven, 3000, Belgium
  • Klinické centrum ISCARE
    Praha, 17004, Czechia
  • Orlicko-ustecka nemocnice
    Ústí Nad Orlicí, 56218, Czechia
  • CHRU de Lille
    Lille, 59037, France
  • CHU de Nantes
    Nantes, 44093, France
  • CHU de Nice
    Nice, 06202, France
  • CHU Saint Etienne - CHU Hopital Nord
    St Priest en Jarez, 42270, France
  • Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie
    Berlin, 12200, Germany
  • Akademisches Lehrkrankenhaus Christian-Albrechts-Universität zu Kiel
    Hamburg, 22559, Germany
  • DRC Gyógyszervizsgáló Központ Kft
    Balatonfüred, H-8230, Hungary
  • Belgyógyászati Klinika
    Budapest, H-1088, Hungary
  • Vasútegészségügyi Nonprofit Közhasznú Kft.,
    Debrecen, H-4025, Hungary
  • KO-Med
    Lublin, Poland
  • Medpolonia Poznań
    Poznań, 60693, Poland
  • NZOZ ViVamed
    Warsaw, 03-580, Poland
  • Centrum Badań Klinicznych Lekarze Sp.p
    Wrocław, 51-161, Poland
  • Centrum Badań
    Łódź, 90302, Poland
  • Hospital RAMÓN Y CAJAL
    Madrid, 28034, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jul 2018, 8 months.

Results were first posted in Feb 2023, 4 years 6 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 8 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2017
First posted
Mar 28, 2017
StartActual
Nov 16, 2017
Primary completionActual
Jul 25, 2018
CompletionActual
Feb 4, 2019
Results first posted
Feb 8, 2023
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03093259
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Mar 28, 2017
Start date
Nov 16, 2017
Primary completion
Jul 25, 2018
Completion
Feb 4, 2019
Results posted
Feb 8, 2023
Last update
Jun 3, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion